- Home
- IMMX vs ICCC Comparison
IMMX vs ICCC Comparison
Compare IMMX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ICCC
- Stock Information
- Founded
- IMMX 2014
- ICCC 1982
- Country
- IMMX United States
- ICCC United States
- Employees
- IMMX N/A
- ICCC N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- ICCC Health Care
- Exchange
- IMMX Nasdaq
- ICCC Nasdaq
- Market Cap
- IMMX 61.1M
- ICCC 60.1M
- IPO Year
- IMMX 2021
- ICCC 1987
- Fundamental
- Price
- IMMX $2.19
- ICCC $6.92
- Analyst Decision
- IMMX Strong Buy
- ICCC
- Analyst Count
- IMMX 1
- ICCC 0
- Target Price
- IMMX $7.00
- ICCC N/A
- AVG Volume (30 Days)
- IMMX 261.4K
- ICCC 44.4K
- Earning Date
- IMMX 08-11-2025
- ICCC 08-12-2025
- Dividend Yield
- IMMX N/A
- ICCC N/A
- EPS Growth
- IMMX N/A
- ICCC N/A
- EPS
- IMMX N/A
- ICCC N/A
- Revenue
- IMMX N/A
- ICCC $27,302,766.00
- Revenue This Year
- IMMX N/A
- ICCC N/A
- Revenue Next Year
- IMMX N/A
- ICCC N/A
- P/E Ratio
- IMMX N/A
- ICCC N/A
- Revenue Growth
- IMMX N/A
- ICCC 28.29
- 52 Week Low
- IMMX $1.26
- ICCC $3.34
- 52 Week High
- IMMX $3.00
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- IMMX 45.97
- ICCC 56.89
- Support Level
- IMMX $2.16
- ICCC $5.63
- Resistance Level
- IMMX $2.31
- ICCC $7.14
- Average True Range (ATR)
- IMMX 0.17
- ICCC 0.57
- MACD
- IMMX -0.04
- ICCC 0.00
- Stochastic Oscillator
- IMMX 11.14
- ICCC 69.38
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.